HaemaLogiX is a clinical stage Australian biotech company, advancing a pipeline of next generation immunotherapies for blood cancers and B-cell disorders. Our key focus is treating multiple myeloma: the world’s second largest blood cancer and a disease for which there is currently no cure.
Read moreHaemaLogiX’s novel immunotherapies bind to unexploited and unique targets (antigens) expressed on the cell surface of cancerous plasma cells in patients with multiple myeloma, AL amyloidosis and some types of autoimmune diseases. Plasma cells are a type of white blood cell known as B-cells. The targets, called kappa myeloma antigen (KMA) and lambda myeloma antigen (LMA), are not present on normal healthy plasma cells, enabling a highly selective and innovative alternative to current treatment targets. The detection of KMA and LMA is unique to HaemaLogiX’s immunotherapies and currently there are no competing therapies in the market, providing a distinct competitive advantage.
Our immunotherapies specifically target KMA or LMA.
KMA and LMA are specifically targeted by novel human monoclonal antibodies called KappaMab and LambdaMab that attach to the cell surface of the cancerous plasma cells and direct the immune system to destroy them. This specificity may increase on-target efficacy and reduce off-target side effects, preserving the patients immune system and therefore protection against life threatening infections associated with off-target side effects. This mechanism of action delivers an alternative and potentially safer therapeutic approach compared to the current stand of care treatments.
In addition, completed clinical studies have demonstrated that KappaMab enhances the current standard-of-care myeloma treatments called immunomodulatory drugs (IMiDs) and offers a compelling combination therapy option for patients living with a disease that currently has no cure.
KappaMab is a therapeutic monoclonal antibody created to target and destroy cancerous plasma cells in blood diseases like multiple myeloma. It is a humanised monoclonal antibody that is designed to specifically bind to KMA and induce the patient’s own immune system to destroy the myeloma cell.
More +KMA.CAR-T cell therapy harnesses the patient’s own T cells (T cells are a type of immune cell) and genetically modifies them to recognise and directly destroy cancerous plasma cells that express KMA.
More +
Antibodies and CAR-T cell immunotherapies that target LMA are in preclinical development for patients diagnosed with lambda-positive antigen expression. Two LambdaMab monoclonal antibodies with distinct binding characteristics are in pre-clinical development for both multiple myeloma and AL amyloidosis.
More +
These are engineered antibodies called T cell engagers that are designed to attach to multiple myeloma plasma cells expressing either KMA or LMA and to simultaneously engage a T cell through its specific cell surface target called CD3. This dual action brings the patient’s own T cells into direct contact with the myeloma cancer cells, enabling targeted T cell mediated cell killing. These T cell engagers that bind to either KMA or LMA and CD3 are in discovery phase.
More +We're developing a suite of diverse immunotherapies including monoclonal antibodies, CAR-T cells and bispecific antibodies, with a key focus on treating multiple myeloma and early investigation of AL Amyloidosis.
HaemaLogiX Ltd, a clinical stage Australian biotech company developing novel immunotherapies for patients with blood cancers (HaemaLogiX), provides the following personnel update.
Read More +HaemaLogiX was pleased to attend the prestigious International Myeloma Society (IMS) Annual Meeting & Exposition, held last week from 14 – 17 September, 2025 in Toronto, Canada.
Read More +HaemaLogiX was honoured to be awarded the “Most Promising CAR-T Pipeline in APAC” at the Asia Pacific CGT Excellence Awards 2025, held in Singapore last night.
Read More +HaemalogiX CEO Damian Clarke-Bruce presented at the 19th Bioshares Biotech Summit in Hobart, showcasing the company’s pioneering immunotherapies for multiple myeloma and B-cell disorders.
Read More +